Search

Displaying results 3861 - 3870 of 8698 in total
  1. Drug

    Butorphanol

    go.drugbank.com/drugs/DB00611
    ApprovedIllicitVet approved

    A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.

  2. Drug

    Midostaurin

    go.drugbank.com/drugs/DB06595
    ApprovedInvestigational

    Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. … It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.

    Categories: Receptor Tyrosine Kinase Inhibitors, Cytochrome P-450 CYP1A2 Inducers
  3. Drug

    Scorpion (centruroides) immune Fab2 antivenin (equine)

    go.drugbank.com/drugs/DB13905
    Approved

    Severe scorpion stings may cause loss of muscle control and respiratory failure, warranting heavy sedation and hospitalization in an intensive care unit. … Envenomation by a scorpion sting can result in serious cardiovascular effects [A32483].

  4. Drug

    Cefamandole

    go.drugbank.com/drugs/DB01326
    ApprovedWithdrawn

    Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Methantheline

    go.drugbank.com/drugs/DB00940
    Approved

    Methantheline is a synthetic antispasmodic. Antispasmodics are used to relieve cramps or spasms of the stomach, intestines, and bladder. Methantheline is used to treat intestine or stomach ulcers (peptic ulcer disease), intestine problem...

    Categories: Drugs for Functional Gastrointestinal Disorders
  6. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L53393] It is additionally under investigation for maternal use and use in children.[A274028,L53438,L53443]

  7. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    [A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  8. Target

    Alpha-2 adrenergic receptors

    go.drugbank.com/bio_entities/BE0004864
    TargetHumans

    Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression (...

    Polypeptides: Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptorSynonyms: Alpha-2 adrenergic receptor subtype C10, Alpha-2 adrenergic receptor subtype C2
  9. Drug

    Cipepofol

    go.drugbank.com/drugs/DB16295
    ApprovedInvestigational

    [L63931] Cipepofol is approved in the United States for induction of general anesthesia in adults undergoing surgery, an approval Haisco announced on June 1, 2026. … [L63931] It is indicated only for induction of general anesthesia, with another agent used up for maintenance.

  10. Drug

    Gremubamab

    go.drugbank.com/drugs/DB15014
    Investigational

    Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).